Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2)
Traumatic Optic Neuropathy
About this trial
This is an interventional treatment trial for Traumatic Optic Neuropathy focused on measuring Traumatic optic neuropathy, Erythropoietin, EPO, Eprex
Eligibility Criteria
Inclusion Criteria:
- Having indirect traumatic optic neuropathy(with normal eye and fundus exam)
- Trauma to treatment interval of 3 weeks and less
- Age of 7 years and more
Exclusion Criteria:
- Direct optic neuropathy,
- Glaucoma,
- Any retinopathy
- Globe laceration
- Age under 7
- Hypertension,
- Polycythemia,
- Creatinin more than 3 mg/dl,
- Sensitivity to EPO
- Patients who have received any other form of treatment for their traumatic optic neuropathy
Sites / Locations
- Iran University of Medical Sciences
- Mashhad University of Medical Sciences
- Tehran University of Medical Sciences
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Group 1
Group 2
Group 3
Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)